Literature DB >> 9699129

Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

S Borgato1, L Persani, R Romoli, D Cortelazzi, A Spada, P Beck-Peccoz.   

Abstract

It has been reported that serum FSH bioactivity and inhibin levels can be used as markers of the presence of true gonadotropin-secreting pituitary adenoma (Gn-oma). To verify this hypothesis, we have investigated the bioactivity of FSH and serum inhibin alpha-alpha and alpha-beta A levels in a series of patients with either Gn-oma or nonfunctioning pituitary adenoma (NFPA). Nine patients with Gn-oma (6 men and 3 women), 21 with NFPA (9 men and 12 women) and 30 normal subjects were included in the study. We studied FSH biological activity (FSH-B) by using Sertoli cell aromatase bioassay (SAB) and alpha-alpha and alpha-beta A inhibin levels by two noncompetitive immunometric assays (IEMA). In male patients with Gn-oma, serum immunoreactive FSH (FSH-I) and FSH-B levels ranged from 5.1 to 35.5 U/L and from 8.3 to 48 U/L, respectively, FSH B/I ratio being elevated in 2 (2.5 and 4.1; normal male range: 0.3-1.5), while female patients with Gn-oma had serum FSH-I and FSH-B levels ranging from 43.2 to 162 U/L and from 41.2 to 112.8 U/l, respectively, with a normal FSH B/I ratio. In male patients with NFPA, FSH-I and FSH-B levels ranged from 2.7 to 10.7 U/l and from 2.4 to 11.4 U/l while in females they ranged from 3.4 to 67.9 and from 4.6 to 60.8 U/l, respectively. FSH B/I ratio was elevated in 1 male (3.3) and normal in the remaining patients with NFPA. Serum alpha-alpha inhibin levels were normal or low in patients with Gn-oma and NFPA, while alpha-beta A inhibin concentrations were slightly elevated in 1 of 6 postmenopausal women (0.9; normal range < 0.7 U/ml). The present study confirms and extends previous reports indicating that male patients with Gn-oma may secrete FSH molecules with increased bioactivity. However, this abnormality was also observed in one male patient with NFPA. Moreover, the measurement of inhibin levels does not appear to be a reliable in vivo marker of pituitary tumors of gonadotroph origin, as it was normal or low in almost all patients with either Gn-oma or NFPA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699129     DOI: 10.1007/BF03350773

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Inhibin-B: a likely candidate for the physiologically important form of inhibin in men.

Authors:  P J Illingworth; N P Groome; W Byrd; W E Rainey; A S McNeilly; J P Mather; W J Bremner
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

2.  The significance of alpha-subunit as a tumor marker for gonadotropin-producing pituitary adenomas.

Authors:  R Demura; K Jibiki; O Kubo; E Odagiri; H Demura; K Kitamura; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

3.  Gonadotroph adenomas in men produce biologically active follicle-stimulating hormone.

Authors:  A B Galway; A J Hsueh; L Daneshdoost; M H Zhou; S N Pavlou; P J Snyder
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

4.  Immunodetection of glycoprotein hormone subunits in nonfunctioning and glycoprotein hormone-secreting pituitary adenomas.

Authors:  K Saccomanno; M Bassetti; A Lania; M Losa; G Faglia; A Spada
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

5.  Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.

Authors:  D J Kwekkeboom; F H de Jong; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1989-06       Impact factor: 5.958

6.  Secretion of uncombined subunits of luteinizing hormone by gonadotroph cell adenomas.

Authors:  P J Snyder; H M Bashey; S U Kim; S C Chappel
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

7.  Concanavalin A affinity chromatography of human serum gonadotropins: evidence for changes of carbohydrate structure in different clinical conditions.

Authors:  M J Papandreou; C Asteria; K Pettersson; C Ronin; P Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

8.  Glycoprotein hormone alpha-subunit in pituitary adenomas.

Authors:  P Beck-Peccoz; L Persani; G Faglia
Journal:  Trends Endocrinol Metab       Date:  1992-03       Impact factor: 12.015

9.  Recognition of gonadotroph adenomas in women.

Authors:  L Daneshdoost; T A Gennarelli; H M Bashey; P J Savino; R C Sergott; T M Bosley; P J Snyder
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

10.  Follicle-stimulating hormone-secreting pituitary tumor with concomitant elevation of serum alpha-subunit levels.

Authors:  J L Borges; E C Ridgway; K Kovacs; A D Rogol; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

View more
  4 in total

1.  Testicular enlargement in a patient with a FSH-secreting pituitary adenoma.

Authors:  Per Dahlqvist; Lars-Owe D Koskinen; Thomas Brännström; Erik Hägg
Journal:  Endocrine       Date:  2010-01-20       Impact factor: 3.633

2.  Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions.

Authors:  G M Gambino; P Beck-Peccoz; S Borgato; G Faglia; A Spada; L Persani
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

3.  Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome.

Authors:  Sayaka Uchida; Hiroshi Uchida; Tetsuo Maruyama; Takashi Kajitani; Hideyuki Oda; Kaoru Miyazaki; Maki Kagami; Yasunori Yoshimura
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

Review 4.  Updating the Landscape for Functioning Gonadotroph Tumors.

Authors:  Georgia Ntali; Cristina Capatina
Journal:  Medicina (Kaunas)       Date:  2022-08-08       Impact factor: 2.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.